IP Library › Granted Patent US 12,540,198
Granted Patent B2
US 12,540,198 · App. 17/241,181 · Granted Feb 3, 2026

Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof

Inventors: Dunja Urosev (Vancouver, CA); Stacey A.L. Tom-Yew (Coquitlam, CA); Leonard G. Presta (San Francisco, CA); Mario Sanches (Vancouver, CA)
Assignee: ZYMEWORKS BC INC.
C07K16/46C07K16/244C07K16/32C07K16/468C07K2317/21C07K2317/24C07K2317/31C07K2317/522C07K2317/55C07K2317/56C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,540,198
App. No.
17/241,181
Granted
Feb 3, 2026
Kind
B2
Abstract

Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the C H1 and/or C L domains, in the V H and/or V L domains, or a combination thereof.

Claims (102)

1 . An antigen-binding polypeptide construct comprising a first heterodimer and a second heterodimer,

the first heterodimer (H1L1) comprising a first IgG heavy chain polypeptide sequence (H1), and a lambda light chain polypeptide sequence (L1) that form a first Fab region that specifically binds to a first antigen; and the second heterodimer (H2L2) comprising a second IgG heavy chain polypeptide sequence (H2), and a kappa light chain polypeptide sequence (L2) that form a second Fab region that specifically binds to a second antigen,

wherein:

H1 is distinct from H2, and H1 and H2 each comprise a heavy chain variable domain (VH domain) and a heavy chain constant domain 1 (CH1 domain);

L1 comprises a lambda light chain variable (VL-lambda) domain and a lambda light chain constant (CL-lambda) domain, and L2 comprises a kappa light chain variable (VL-kappa) domain and a kappa light chain constant (CL-kappa) domain;

H1, H2, L1, and/or L2 comprise amino acid substitutions that promote preferential pairing of H1 with L1 as compared to L2, and/or that promote preferential pairing of H2 with L2 as compared to L1, at positions identified according to the Kabat numbering system; and

a) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 129T, 176E, and 178E, H2 comprises amino acid substitutions 39E, 124E, 145T, and 179E, and L2 comprises amino acid substitutions 38R, 131R, 133G, and 176R;

b) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 129T, 176E, and 178E, H2 comprises amino acid substitutions 45P, 124E, 145T, and 179E, and L2 comprises amino acid substitutions 44F, 131R, 133G, and 176R;

c) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 124E and 188W, and L2 comprises amino acid substitutions 133G, 176R, and 178A;

d) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 124E, 186I, and 188W, and L2 comprises amino acid substitutions 133G, 176R, and 178A;

e) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitution 124E, and L2 comprises amino acid substitutions 133G and 176R;

f) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 124E and 188W, and L2 comprises amino acid substitutions 133A, 176K, and 178A;

g) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 124E, 186I and 188W, and L2 comprises amino acid substitutions 133A, 176K, and 178A;

h) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitution 124E, and L2 comprises amino acid substitutions 133A and 176K;

i) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178R;

j) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178L;

k) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178K;

l) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 124E, 145T, 179E, and 188W, and L2 comprises amino acid substitutions 131R, 133G, 176R, and 178A;

m) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 124E, 145T, 179E, 186I, and 188W, and L2 comprises amino acid substitutions 131R, 133G, 176R, and 178A;

n) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 124E, 145T, and 179E, and L2 comprises amino acid substitutions 131R, 133G, and 176R;

o) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 124E, 145T, 179E, and 188W, and L2 comprises amino acid substitutions 131K, 133G, 176R, and 178A;

p) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 124E, 145T, 179E, 186I, and 188W, and L2 comprises amino acid substitutions 131K, 133G, 176R, and 178A;

q) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 124E, 145T, and 179E, and L2 comprises amino acid substitutions 131K, 133G, and 176R;

r) H1 comprises amino acid substitution 188A, L1 comprises amino acid substitutions 176A and 178W, H2 comprises amino acid substitutions 186L and 188W, and L2 comprises amino acid substitutions 176A and 178A;

s) H2 comprises amino acid substitutions 186L and 188W, and L2 comprises amino acid substitution 176V;

t) H2 comprises amino acid substitutions 186I and 188W, and L2 comprises amino acid substitution 176V;

u) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178R;

v) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178K;

w) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133I, 176D, and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178R;

x) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133I, 176D, and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178L;

y) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133I, 176D, and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178K;

z) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176D and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178R;

aa) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176D and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178L;

bb) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 133I, 176D, and 178E, H2 comprises amino acid substitutions 124E, 145T, and 179E, and L2 comprises amino acid substitutions 131K, 133G, and 176R;

cc) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 133I, 176D, and 178E, H2 comprises amino acid substitutions 124E, 145T, and 179E, and L2 comprises amino acid substitutions 131R, 133G, and 176R;

dd) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133I, 176D, and 178E, H2 comprises amino acid substitutions 124E, 145T, and 179E, and L2 comprises amino acid substitutions 131K, 133G, and 176R;

ee) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitution 124E, and L2 comprises amino acid substitutions 133G and 176R;

ff) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 129T, 176E, and 178E, H2 comprises amino acid substitutions 124E, 145T, and 179E, and L2 comprises amino acid substitutions 131R, 133G, and 176R;

gg) H1 comprises amino acid substitutions 139W and 188K, L1 comprises amino acid substitutions 129T, 176D, and 178T, H2 comprises amino acid substitutions 145T and 186E, and L2 comprises amino acid substitutions 131K, 135W, and 176K;

hh) H1 comprises amino acid substitutions 139W and 188K, L1 comprises amino acid substitutions 129T, 176E, and 178E, H2 comprises amino acid substitutions 145T and 186E, and L2 comprises amino acid substitutions 131K, 135W, and 176K;

ii) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 129T and 178E, H2 comprises amino acid substitutions 145T and 186E, and L2 comprises amino acid substitutions 131K and 176K;

jj) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 129T and 178D, H2 comprises amino acid substitutions 145T and 186E, and L2 comprises amino acid substitutions 131K and 176K;

kk) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 129T, 176D, and 178T, H2 comprises amino acid substitutions 145T and 186E, and L2 comprises amino acid substitutions 131K and 176K;

ll) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 129T, 176E, and 178E, H2 comprises amino acid substitutions 145T and 186E, and L2 comprises amino acid substitutions 131K and 176K;

mm) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitutions 124E and 188W, and L2 comprises amino acid substitutions 133G, 176R, and 178A;

nn) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitutions 124E, 186I, and 188W, and L2 comprises amino acid substitutions 133G, 176R, and 178A;

oo) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitutions 124E and 188W, and L2 comprises amino acid substitutions 133A, 176K, and 178A;

pp) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133I, 176D, and 178E, H2 comprises amino acid substitutions 124E, 145T, and 179E, and L2 comprises amino acid substitutions 131R, 133G, and 176R;

qq) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitutions 124E, 186I, and 188W, and L2 comprises amino acid substitutions 133A, 176K, and 178A;

rr) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitution 124E, and L2 comprises amino acid substitutions 133A and 176K;

ss) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitutions 124E, 145T, 179E, and 188W, and L2 comprises amino acid substitutions 131R, 133G, 176R, and 178A;

tt) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitutions 124E, 145T, 179E, 186I, and 188W, and L2 comprises amino acid substitutions 131R, 133G, 176R, and 178A;

uu) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitutions 124E, 145T, and 179E, and L2 comprises amino acid substitutions 131R, 133G, and 176R;

vv) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitutions 124E, 145T, 179E, and 188W, and L2 comprises amino acid substitutions 131K, 133G, 176R, and 178A;

ww) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitutions 124E, 145T, 179E, 186I, and 188W, and L2 comprises amino acid substitutions 131K, 133G, 176R, and 178A;

xx) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133L, 176D, and 178E, H2 comprises amino acid substitutions 124E, 145T, and 179E, and L2 comprises amino acid substitutions 131K, 133G, and 176R;

yy) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133I, 176E, and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178R;

zz) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133I, 176E, and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178L;

aaa) H1 comprises amino acid substitutions 177I and 188K, L1 comprises amino acid substitutions 133I, 176E, and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178K; or

bbb) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176D and 178E, H2 comprises amino acid substitutions 145T, 177D, and 188D, and L2 comprises amino acid substitutions 176K and 178K.

2 . The construct of claim 1 , wherein the amino acid substitutions promote preferential pairing of H1 with L1 as compared to L2, and/or that promote preferential pairing of H2 with L2 as compared to L1, when H1, H2, L1 and L2 are co-expressed in a cell or a mammalian cell, or when H1, H2, L1 and L2 are co-expressed in a cell-free expression system, or when H1 and L1 are produced in a cell and H2 and L2 are produced in a different cell and the products of the two cells are mixed via a redox production method, or when H1 and L1 are produced in a cell-free expression system and H2 and L2 are produced in a different cell-free expression system and the products of the two cell-free expression systems are mixed.

3 . The construct according to claim 2 , wherein the sequences of each of H1, H2, L1, and L2 are derived from human sequences or humanized sequences.

4 . The construct of claim 3 , wherein the construct further comprises a dimeric Fc having two Fc polypeptides each comprising a CH2 domain sequence and a CH3 domain sequence, and wherein one Fc polypeptide is coupled with or without linkers to the first Fab region and the other Fc polypeptide is coupled with or without linkers to second Fab region.

5 . The construct of claim 4 , wherein the Fc is a human Fc.

6 . The construct of claim 5 , wherein the human Fc comprises one or more substitutions as compared to wild type in at least one of the CH3 domain sequences that promote preferential pairing between heterodimeric CH3 domain sequences relative to homodimeric CH3 domain sequences.

7 . The construct of claim 6 , wherein the human Fc comprises:

i) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392M_T394W in the second Fc polypeptide;

ii) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392L_T394W in the second Fc polypeptide;

iii) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392L_T394W in the second Fc polypeptide;

iv) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392M_T394W in the second Fc polypeptide; or

v) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_S400E_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_N390R_K392M_T394W in the second Fc polypeptide,

wherein the numbering of amino acid residues in the Fc is according to EU numbering.

8 . The construct of claim 4 , wherein the Fc comprises one or more modifications to promote selective binding of Fc-gamma receptors, to reduce or eliminate binding to Fc-gamma receptors, or to promote binding to FcRn.

9 . The construct of claim 4 , wherein the linkers are one or more polypeptide linkers.

10 . The construct according to claim 1 , conjugated to a therapeutic agent.

11 . A polynucleotide or set of polynucleotides that encodes the construct of claim 1 .

12 . A vector or set of vectors comprising one or more of the polynucleotides or sets of polynucleotides according to claim 11 .

13 . An isolated cell comprising the polynucleotide or set of polynucleotides according to claim 11 .

14 . A pharmaceutical composition comprising the antigen-binding polypeptide construct of claim 1 and a pharmaceutically acceptable carrier.

15 . A method of preparing the construct according to claim 1 , comprising the steps of:

(a) obtaining a host cell comprising a polynucleotide or set of polynucleotides encoding the antigen-binding polypeptide construct;

(b) culturing the host cell in a host cell culture under conditions that allow expression of the antigen-binding polypeptide construct, and

(c) collecting the antigen-binding polypeptide construct from the host cell culture.

16 . The construct according to claim 1 , wherein:

a) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 124E, 145T, 179E, and 188W, and L2 comprises amino acid substitutions 131R, 133G, 176R, and 178A, or

b) H1 comprises amino acid substitution 188K, L1 comprises amino acid substitutions 176E and 178E, H2 comprises amino acid substitutions 124E, 145T, and 179E, and L2 comprises amino acid substitutions 131R, 133G, and 176R.

17 . The construct of claim 16 , wherein the amino acid substitutions promote preferential pairing of H1 with L1 as compared to L2, and/or that promote preferential pairing of H2 with L2 as compared to L1, when H1, H2, L1 and L2 are co-expressed in a cell or a mammalian cell, or when H1, H2, L1 and L2 are co-expressed in a cell-free expression system, or when H1 and L1 are produced in a cell and H2 and L2 are produced in a different cell and the products of the two cells are mixed via a redox production method, or when H1 and L1 are produced in a cell-free expression system and H2 and L2 are produced in a different cell-free expression system and the products of the two cell-free expression systems are mixed.

18 . The construct according to claim 17 , wherein the sequences of each of H1, H2, L1, and L2 are derived from human sequences or humanized sequences.

19 . The construct of claim 18 , wherein the construct further comprises a dimeric Fc having two Fc polypeptides each comprising a CH2 domain sequence and a CH3 domain sequence, and wherein one Fc polypeptide is coupled with or without linkers to the first Fab region and the other Fc polypeptide is coupled with or without linkers to second Fab region.

20 . The construct of claim 19 , wherein the Fc is a human Fc.

21 . The construct of claim 20 , wherein the human Fc comprises one or more substitutions as compared to wild type in at least one of the CH3 domain sequences that promote preferential pairing between heterodimeric CH3 domain sequences relative to homodimeric CH3 domain sequences.

22 . The construct of claim 21 , wherein the human Fc comprises:

i) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392M_T394W in the second Fc polypeptide;

ii) a heterodimeric IgG1 Fc having the substitutions L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T366L_K392L_T394W in the second Fc polypeptide;

iii) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392L_T394W in the second Fc polypeptide;

iv) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_K392M_T394W in the second Fc polypeptide; or

v) a heterodimeric IgG1 Fc having the substitutions T350V_L351Y_S400E_F405A_Y407V in the first Fc polypeptide, and the substitutions T350V_T366L_N390R_K392M_T394W in the second Fc polypeptide,

wherein the numbering of amino acid residues in the Fc is according to EU numbering.

23 . The construct of claim 19 , wherein the Fc comprises one or more modifications to promote selective binding of Fc-gamma receptors, to reduce or eliminate binding to Fc-gamma receptors, or to promote binding to FcRn.

24 . The construct of claim 19 , wherein the linkers are one or more polypeptide linkers.

25 . The construct according to claim 16 , conjugated to a therapeutic agent.

26 . The construct of claim 4 , wherein the one or more linkers comprise one or more antibody hinge regions.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2026
From: SANCHES, MARIO; UROSEV, DUNJA
To: ZYMEWORKS INC.
Reel/Frame 073988/0098 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2026
From: TOM-YEW, STACEY A. L.; PRESTA, LEONARD G.
To: ZYMEWORKS INC.
Reel/Frame 073988/0153 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2026
From: SANCHES, MARIO; UROSEV, DUNJA
To: ZYMEWORKS INC.
Reel/Frame 073988/0217 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2026
From: TOM-YEW, STACEY A. L.; PRESTA, LEONARD G.
To: ZYMEWORKS INC.
Reel/Frame 073988/0268 →
CHANGE OF NAME Recorded Apr 21, 2023
From: ZYMEWORKS INC.
To: ZYMEWORKS BC INC.
Reel/Frame 063400/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2021
From: UROSEV, DUNJA; SANCHES, MARIO; PRESTA, LEONARD G.; TOM-YEW, STACEY A.L.
To: ZYMEWORKS INC.
Reel/Frame 056116/0964 →
Continuity (4)
Division 15765574
Provisional Application 62261769 · Dec 1, 2015
Provisional Application 62239206 · Oct 8, 2015
Related Publication 20210355239A1 · Nov 18, 2021
References Cited (243)
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5807706A · Carter et al. · 1998 [cited by applicant]
US 5821333A · Carter et al. · 1998 [cited by applicant]
US 6809185B1 · Schoonjans et al. · 2004 [cited by applicant]
US 7183076B2 · Arathoon et al. · 2007 [cited by applicant]
US 7642228B2 · Carter et al. · 2010 [cited by applicant]
US 7695936B2 · Carter et al. · 2010 [cited by applicant]
US 7947271B2 · Browning et al. · 2011 [cited by applicant]
US 7951917B1 · Arathoon et al. · 2011 [cited by applicant]
US 8501185B2 · Heitner Hansen et al. · 2013 [cited by applicant]
US 8592562B2 · Kannan et al. · 2013 [cited by applicant]
US 9499634B2 · Dixit et al. · 2016 [cited by applicant]
US 9527927B2 · Chowdhury et al. · 2016 [cited by applicant]
US 9708388B2 · Dutalys · 2017 [cited by applicant]
US 9771573B2 · Ohrn et al. · 2017 [cited by applicant]
US 9914785B2 · Corper et al. · 2018 [cited by applicant]
US 10077298B2 · Corper · 2018 [cited by applicant]
US 10392438B2 · Bennett · 2019 [cited by examiner]
US 11078296B2 · Corper · 2021 [cited by applicant]
US 11161915B2 · Urosev · 2021 [cited by examiner]
US 11286293B2 · Corper · 2022 [cited by applicant]
US 11306156B2 · Sanches · 2022 [cited by examiner]
US 20030003502A1 · Jardetzky et al. · 2003 [cited by applicant]
US 20030129659A1 · Whelihan et al. · 2003 [cited by applicant]
US 20060136184A1 · Gustafsson et al. · 2006 [cited by applicant]
US 20070196363A1 · Arathoon et al. · 2007 [cited by applicant]
US 20080050370A1 · Glaser et al. · 2008 [cited by applicant]
US 20090162360A1 · Klein et al. · 2009 [cited by applicant]
US 20090182127A1 · Kjaergaard et al. · 2009 [cited by applicant]
US 20090232811A1 · Klein et al. · 2009 [cited by applicant]
US 20090263392A1 · Igawa et al. · 2009 [cited by applicant]
US 20100015133A1 · Igawa et al. · 2010 [cited by applicant]
US 20100075326A1 · Jin et al. · 2010 [cited by applicant]
US 20100105874A1 · Schuurman et al. · 2010 [cited by applicant]
US 20100256338A1 · Brinkmann et al. · 2010 [cited by applicant]
US 20100286374A1 · Kannan et al. · 2010 [cited by applicant]
US 20100322935A1 · Croasdale et al. · 2010 [cited by applicant]
US 20100331527A1 · Davis et al. · 2010 [cited by applicant]
US 20110008345A1 · Ashman et al. · 2011 [cited by applicant]
US 20110275787A1 · Kufer et al. · 2011 [cited by applicant]
US 20110287009A1 · Scheer et al. · 2011 [cited by applicant]
US 20110293613A1 · Brinkmann et al. · 2011 [cited by applicant]
US 20120143580A1 · Constantine et al. · 2012 [cited by applicant]
US 20120149876A1 · Von Kreudenstein et al. · 2012 [cited by applicant]
US 20120244578A1 · Kannan et al. · 2012 [cited by applicant]
US 20130078249A1 · Ast et al. · 2013 [cited by applicant]
US 20130195849A1 · Spreter Von Kreudenstein et al. · 2013 [cited by applicant]
US 20130336973A1 · Spreter Von Kreudenstein et al. · 2013 [cited by applicant]
US 20140066599A2 · Blein et al. · 2014 [cited by applicant]
US 20140154254A1 · Kannan et al. · 2014 [cited by applicant]
US 20140179547A1 · Fischer et al. · 2014 [cited by applicant]
US 20140187753A1 · Blein et al. · 2014 [cited by applicant]
US 20140200331A1 · Corper et al. · 2014 [cited by applicant]
US 20140370020A1 · Kuramochi et al. · 2014 [cited by applicant]
US 20150284470A1 · Spreter Von Kreudenstein et al. · 2015 [cited by applicant]
US 20150307594A1 · Corper et al. · 2015 [cited by applicant]
US 20160083480A1 · Ng et al. · 2016 [cited by applicant]
US 20160257763A1 · Von Kreudenstein et al. · 2016 [cited by applicant]
US 20170204199A1 · Sanches et al. · 2017 [cited by applicant]
US 20180179296A1 · Corper et al. · 2018 [cited by applicant]
US 20190002589A1 · Bardroff et al. · 2019 [cited by applicant]
US 20190085055A1 · Corper et al. · 2019 [cited by applicant]
US 20190218311A1 · Loew et al. · 2019 [cited by applicant]
US 20200123260A1 · Bennett · 2020 [cited by examiner]
US 20220251242A1 · Sanches · 2022 [cited by examiner]
US 20230192795A1 · Codarri · 2023 [cited by examiner]
US 20230265134A1 · Sivasubramanian et al. · 2023 [cited by applicant]
US 20240140978A1 · O'Neill · 2024 [cited by examiner]
CN 108283001 · 2016 [cited by examiner]
EP 2543680 · 2013 [cited by applicant]
WO 199627011 · 1994 [cited by applicant]
WO 2006106905 · 2006 [cited by applicant]
WO 2007110205 · 2007 [cited by applicant]
WO 2009089004 · 2009 [cited by applicant]
WO 199404690 · 2010 [cited by applicant]
WO 2010085682 · 2010 [cited by applicant]
WO 2010115553 · 2010 [cited by applicant]
WO 2011119484A1 · 2011 [cited by applicant]
WO 2011131746 · 2011 [cited by applicant]
WO 2011133886 · 2011 [cited by applicant]
WO 2011147982 · 2011 [cited by applicant]
WO 2012006635 · 2012 [cited by applicant]
WO 2012020096 · 2012 [cited by applicant]
WO 2012023053 · 2012 [cited by applicant]
WO 2012073985 · 2012 [cited by applicant]
WO 2012131555 · 2012 [cited by applicant]
WO 2012143523 · 2012 [cited by applicant]
WO 2012163519A1 · 2012 [cited by applicant]
WO 2013002362 · 2013 [cited by applicant]
WO 2013005194 · 2013 [cited by applicant]
WO 2013060867A2 · 2013 [cited by applicant]
WO 2013065708 · 2013 [cited by applicant]
WO 2013096291 · 2013 [cited by applicant]
WO 2014081955 · 2014 [cited by applicant]
WO 2014082179A1 · 2014 [cited by applicant]
WO 2014124326 · 2014 [cited by applicant]
WO 2014150973A1 · 2014 [cited by applicant]
WO 2015052230 · 2015 [cited by applicant]
WO 2015173756A2 · 2015 [cited by applicant]
WO 2015181805A1 · 2015 [cited by applicant]
WO 2016026943 · 2016 [cited by applicant]
WO 2016172485 · 2016 [cited by applicant]
WO 2017117179 · 2017 [cited by applicant]
WO 2018141894 · 2018 [cited by applicant]
WO 2018158719 · 2018 [cited by applicant]
WO 2018057955 · 2019 [cited by applicant]
U.S. Appl. No. 18/531,328, filed Apr. 2, 2024, O'Neill: Heather. [cited by examiner]
U.S. Appl. No. 15/765,574 Notice of Allowance dated Apr. 26, 2021. [cited by applicant]
U.S. Appl. No. 15/896,170 Notice of Allowance dated Jun. 9, 2021. [cited by applicant]
U.S. Appl. No. 16/122,417 Ex Parte Quayle dated Jul. 8, 2021. [cited by applicant]
U.S. Appl. No. 15/896,170 Office Action dated Sep. 18, 2019. [cited by applicant]
U.S. Appl. No. 15/896,170 Office Action dated May 18, 2020. [cited by applicant]
U.S. Appl. No. 15/314,496 Office Action dated Jan. 6, 2020. [cited by applicant]
U.S. Appl. No. 16/122,417 Office Action dated Jun. 19, 2020. [cited by applicant]
U.S. Appl. No. 16/122,417 Restriction Requirement dated Mar. 6, 2020. [cited by applicant]
Fischer, et al., ‘Exploiting light chaings for the scalable generation and platform purification of native human bispecific igG’, Nature Communications, 2015. [cited by applicant]
International Search Report received in the corresponding PCT Application No. PCT/CA2018/050809, dated Jan. 3, 2019. [cited by applicant]
Lehmann, et al., Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kapp swap of the V [cited by applicant]
Altintas, I., et al., Targeting epidermal growth factor receptor in tumors: From conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. Eur J Pharm Sci. Mar. 12, 2012; 45(4): 399-407. [cited by applicant]
Atwell et al., Stable Heterodimers from Remodeling the Domain Interface of a Homodimer Using a Phage Display Library, Journal of Molecular Biology, vol. 270, No. 1, Jul. 4, 1997, pp. 26-35. [cited by applicant]
Beck et al., Strategies and Challenges for the Next Generation of Therapeutic Antibodies, Nature Reviews Immunology, vol. 10, No. 5, May 2010, pp. 345-352. [cited by applicant]
Chames et al., Therapeutic Antibodies: Successes, Limitations and Hopes for the Future, British Journal of Pharmacology, vol. 157, No. 2, 2009, pp. 220-223. [cited by applicant]
Colman, Effects of Amino Acid Sequence Changes on Antibody-antigen Interactions, Research in Immunology, vol. 145, No. 1, Jan. 1994, pp. 33-36. [cited by applicant]
Coloma et al., Design and Production of Novel Tetravalent Bispecific Antibodies, Nature Biotechnology, vol. 15, No. 2, Feb. 1997, pp. 159-163. [cited by applicant]
Dall'acqua et al., Contribution of Domain Interface Residues to the Stability of Antibody CH3 Domain Homodimers, Biochemistry, American Chemical Society, vol. 37, No. 26, Jun. 30, 1998, pp. 9266-9273. [cited by applicant]
Davis et al., SEEDbodies: Fusion Proteins Based on Strand-exchange Engineered Domain (SEED) CH3 Heterodimers in an Fc Analogue Platform for Asymmetric Binders or Immunofusions and Bispecific Antibodies, Protein Engineer… [cited by applicant]
Demarest et al., Antibody Therapeutics, Antibody Engineering, and the Merits of Protein Stability, Current Opinion in Drug Discovery and Development vol. 11, No. 5, Sep. 2008, pp. 675-687. [cited by applicant]
Demarest et al., Optimization of the Antibody CH3 Domain by Residue Frequency Analysis of IgG Sequences, Journal of Molecular Biology, vol. 335, No. 1, Jan. 2, 2004, pp. 41-48. [cited by applicant]
Edwards, B.M., et al., The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J. Mol. Biol. 2003; 334(1): 103-118. [cited by applicant]
Gramer, M. J., et al., Production of stable bispecific IgG1 by controlled Fab-arm exchange Scalability from bench to large-scale manufacturing by application of standard approaches. mAbs. Nov. 1, 2013;5(6):962-973. [cited by applicant]
Gunasekaran et al., Enhancing Antibody Fc Heterodimer Formation Through Electrostatic Steering Effects: Applications to Bispecific Molecules and Monovalent IgG mailed on J. Biol. Chem., vol. 285, No. 25, Jun. 18, 2010, … [cited by applicant]
Heads, J.T., Relative stabilities of IgG1 and IgG4 Fab Domains: Influence of the Light-Heavy interchain disulfide bond architecture. Protein Science. Jul. 2012; 21(9):1315-1322. [cited by applicant]
Igawa, T., et al., VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. Protein Eng Des Sel. Aug. 2010; 23(8):667-… [cited by applicant]
Jordan et al., Structural Understanding of Stabilization Patterns in Engineered Bispecific Ig-like Antibody Molecules, proteins: structure. Function. And bioinformatics, vol. 77, No. 4, Dec. 1, 2009, pp. 832-841. [cited by applicant]
Kabat, E.A., et al., Sequences of proteins of Immunological Interest. Diae publishing, 5th Ed., vol. 1, 1991, NIH Publication 91-3242 (pp. 647-657, 661-669). [cited by applicant]
Klein et al., Progress in Overcoming the Chain Association Issue in Bispecific Heterodimeric LgG Antibodies, mAbs. vol. 4, No. 6, Nov. 2012, pp. 653-663. [cited by applicant]
Labrijin, A. F., et al., Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. PNAS, Mar. 26, 2013; 110(13):5145-5150. [cited by applicant]
Lewis et al., Generation of Bispecific IgG Antibodies by Structure-Based Design of an Orthogonal Fab Interface, Nature Biotechnology, vol. 32, No. 2, Jan. 26, 2014, pp. 191-198. [cited by applicant]
Lu, D. et al., Fab-scFv Fusion Protein: An Efficient Approach to Production of Bispecific Antibody Fragments mailed on Journal of Immunological Methods, vol. 267, No. 2, 2002, pp. 213-226. [cited by applicant]
Merchant et al., An Efficient Route to Human Bispecific IgG, Nature Biotechnology, vol. 16, No. 7, Jul. 16, 1998, pp. 677-681. [cited by applicant]
Merk et al., Cell-Free Expression of Two Single-Chain Monoclonal Antibodies against Lysozyme: Effect of Domain Arrangement on the Expression, J. Biochem., vol. 125, Dec. 31, 1999, pp. 328-333. [cited by applicant]
Miller et al., Stability Engineering of scFvs for the Development of Bispecific and Multivalent Antibodies, Protein Engineering. Design and selection, Oxford Journal, vol. 23, No. 7., Jul. 1, 2010, pp. 549-557. [cited by applicant]
Moore et al., A Novel Bispecific Antibody Format Enables Simultaneous Bivalent and Monovalent Co-engagement of Distinct Target Antigens, mAbs, vol. 3, No. 6, 2011, pp. 546-557. [cited by applicant]
Padlan, E. A., et al., Antibody Fab assembly: The interface residues between CH1 and CL. Molecular Immunology, Sep. 1986; 23(9):951-960. [cited by applicant]
Presta, et al., Engineering Therapeutic Antibodies for Improved Function, Biochem. Soc. Trans., vol. 30, No. 4, Aug. 2002, pp. 487-490. [cited by applicant]
Ridgway et al., Knobs-into-Holes' Engineering of Antibody CH3 Domains for Heavy Chain Heterodimerization, Protein Engineering, vol. 9, No. 7, Jul. 1996, pp. 617-621. [cited by applicant]
Schaefer, W., et a., Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. PNAS, Jul. 5, 2011; 108(27):11187-11192. [cited by applicant]
Schlatter et al., On the Optimal ratio of Heavy to Light Chain Genes for Efficient Recombinant Antibody Production by CHO Cells, Biotechnology Progress, vol. 21, No. 1, Jan.-Feb. 2005, pp. 122-133. [cited by applicant]
Segal et al., Introduction: Bispecific Antibodies, Journal of Immunological Methods, vol. 248, No. 1-2, Feb. 1, 2001, pp. 1-6. [cited by applicant]
Spreter Von Kreudenstein, T., et al., Improving biophysical properties of a bispecific antibody scaffold to aid developability. Sep./Oct. 2013, mAbs, vol. 5, No. 5, pp. 646-654. [cited by applicant]
Spreter Von Kreudenstein, T., et al., Protein engineering and the use of molecular modeling and simulation: the case of heterodimeric Fe engineering. Methods. Jan. 1, 2014; 65(1):77-94. [cited by applicant]
Stanglmaier et al., Bi20 (fBTA05), a Novel Trifunctional Bispecific Antibody (Anti-CD20 X Anti-CD3), Mediates Efficient Killing of B-cell Lymphoma Cells Even with Very Low CD20 Expression Levels, International Journal o… [cited by applicant]
Strop, P., et al., Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol. Jul. 13, 2012; 420(3):204-219. [cited by applicant]
Suresh et al., Bispecific Monoclonal Antibodies from Hybrid Hybridomas, Methods in Enzymology, vol. 121, 1986, pp. 210-228. [cited by applicant]
Zhu et al., Remodeling Domain Interfaces to Enhance Heterodimer Formation. Protein Science, vol. 6, No. 4, Apr. 1997, pp. 781-788. [cited by applicant]
U.S. Appl. No. 14/648,222, Restriction Requirement issued May 9, 2016. [cited by applicant]
U.S. Appl. No. 14/648,222, Restriction Requirement issued Dec. 2, 2016. [cited by applicant]
U.S. Appl. No. 14/648,222, Non-Final Office Action issued May 16, 2017. [cited by applicant]
U.S. Appl. No. 14/648,222, Final Office Action issued Dec. 29, 2017. [cited by applicant]
U.S. Appl. No. 14/648,222, Notice of Allowance issued May 8, 2018. [cited by applicant]
U.S. Appl. No. 14/092,804, Restriction Requirement dated Jun. 18, 2015. [cited by applicant]
U.S. Appl. No. 14/092,804, Non-Final Office Action dated Sep. 10, 2015. [cited by applicant]
U.S. Appl. No. 14/092,804, Restriction Requirement dated May 12, 2016. [cited by applicant]
U.S. Appl. No. 14/092,804, Final Office Action dated Dec. 29, 2016. [cited by applicant]
U.S. Appl. No. 14/092,804, Notice of Allowance dated Nov. 1, 2017. [cited by applicant]
U.S. Appl. No. 15/896,170, Restriction Requirement dated Jun. 26, 2019. [cited by applicant]
U.S. Appl. No. 15/314,496, Restriction Requirement dated May 8, 2018. [cited by applicant]
U.S. Appl. No. 15/314,496, Non-Final Office Action dated Oct. 17, 2018. [cited by applicant]
U.S. Appl. No. 15/314,496, Final Office Action dated Apr. 24, 2019. [cited by applicant]
U.S. Appl. No. 15/314,496, Final Office Action dated Jul. 28, 2020. [cited by applicant]
Final Office Action dated Feb. 1, 2021 in U.S. Appl. No. 15/896,170. [cited by applicant]
Final Office Action dated Feb. 8, 2021 in U.S. Appl. No. 16/122,417. [cited by applicant]
U.S. Appl. No. 15/314,496—Corrected Notice of Allowability dated Jan. 21, 2022. [cited by applicant]
U.S. Appl. No. 15/314,496—Corrected Notice of Allowability dated Jan. 27, 2022. [cited by applicant]
Notice of Allowance dated Mar. 30, 2021 in U.S. Appl. No. 15/896,170. [cited by applicant]
Non Final Office Action dated Mar. 30, 2021 in U.S. Appl. No. 15/314,496. [cited by applicant]
Chen, Lei, et al., “Preferential Germline Usage and VH/VL Pairing Observed in Human Antibodies selected by mRNA display.”, Protein Engineering, Design & Selection: Peds, Oct. 2015, vol. 28, No. 10, pp. 427-435. [cited by applicant]
Lui, Zhi, et al., “A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatis Steering Mechanism”, Journal of Biological Chemistry, vol. 290, No. 12, Mar. 2015, … [cited by applicant]
Martin, A.C.R., Protein Sequence and Structure Analysis of Antibody Variable Domains. In: Kontermann R., Dübel S. (eds) Antibody Engineering. Springer Protocols Handbooks. Springer, Berlin, Heidelberg. 2010, p. 33-51, p… [cited by applicant]
Arnau J. et al., Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins, Protein expression and purification, 2006, V. 48, N. 1, pp. 1-13, all text, p. 2 in particul… [cited by applicant]
Safdari Y. et al., Antibody humanization methods- and review and update. Biotechnology and Genetic Engineering Reviews, 2013, V. 29, N. 2, pp. 175-186, pp. 178, 180. [cited by applicant]
Shen J. et al., Single variable domain-IgG fusion: a novel recombinant approach to Fc domain-containing bispecific antibodies, Journal of Biological Chemistry, 2006, V. 281, N. 16, p. 10706-10714, p. 10713. [cited by applicant]
Zhu Z. et al., Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F (ab') 2 for efficient lysis of p185HER2 overexpressing tumor cells, International journal of cancer, 1995, V. 62, N. 3, p. 319-324, … [cited by applicant]
Torres M. et al., The immunoglobulin constant region contributes to affinity and specificity, Trends in immunology, 2008, V. 29, N. 2, p. 91-97, p. 93-94. [cited by applicant]
Pakula A.A. et al. Genetic analysis of protein stability and function, Annual review of genetics, 1989, V. 23, N, 1, p. 289-310, p. 305-306. [cited by applicant]
Gasser B. et al., Antibody production with yeasts and filamentous fungi: on the road to large scale? Biotechnology letters, 2007, V. 29, N. 2, pp. 201-212, see p. 208. [cited by applicant]
U.S. Appl. No. 16/122,417, Notice of Allowance, Oct. 18, 2021, 8 pgs. [cited by applicant]
Vidarsson, et al., ‘IgG subclasses and allotypes: from structure to effector functions’, frontiers in Immunology, Immunotherapies and Vaccines, 2014, vol. 5, pp. 1-17. [cited by applicant]
U.S. Appl. No. 13/289,934, Notice of Allowance, Mailed On Sep. 29, 2016, 9 pages. [cited by applicant]
U.S. Appl. No. 14/432,153 , “Corrected Notice of Allowability”, Aug. 18, 2017, 7 pages. [cited by applicant]
U.S. Appl. No. 14/432,153 , Non-Final Office Action, Mailed On Oct. 27, 2016, 10 pages. [cited by applicant]
U.S. Appl. No. 14/432,153 , Notice of Allowance, Mailed On May 15, 2017, 8 pages. [cited by applicant]
U.S. Appl. No. 14/432,153 , “Restriction Requirement”, Jun. 30, 2016, 7 pages. [cited by applicant]
U.S. Appl. No. 14/648,222 , Advisory Action, Mailed On Apr. 20, 2018, 3 pages. [cited by applicant]
U.S. Appl. No. 15/314,496 , Notice of Allowance, Mailed On Dec. 6, 2021, 11 pages. [cited by applicant]
U.S. Appl. No. 15/409,456 , Final Office Action, Mailed On Oct. 24, 2019, 7 pages. [cited by applicant]
U.S. Appl. No. 15/409,456 , Final Office Action, Mailed On May 13, 2020, 8 pages. [cited by applicant]
U.S. Appl. No. 15/409,456 , Non-Final Office Action, Mailed On May 23, 2019, 9 pages. [cited by applicant]
U.S. Appl. No. 15/409,456 , Notice of Allowance, Mailed On Aug. 27, 2020, 7 pages. [cited by applicant]
U.S. Appl. No. 15/409,456 , “Restriction Requirement”, Jan. 10, 2019, 9 pages. [cited by applicant]
U.S. Appl. No. 15/411,799 , Notice of Allowance, Mailed On Jun. 10, 2019, 12 pages. [cited by applicant]
U.S. Appl. No. 15/411,799 , “Restriction Requirement”, Jan. 25, 2019, 9 pages. [cited by applicant]
U.S. Appl. No. 15/765,574, Non-Final Office Action, Mailed On Dec. 27, 2019, 25 pages. [cited by applicant]
U.S. Appl. No. 15/765,574 , Notice of Allowance, Mailed On Sep. 2, 2020, 14 pages. [cited by applicant]
U.S. Appl. No. 15/765,574, Notice of Allowance, Mailed On Jan. 27, 2021 , 8 pages. [cited by applicant]
U.S. Appl. No. 15/765,574 , “Restriction Requirement”, Sep. 10, 2019, 16 pages. [cited by applicant]
“U.S. Appl. No. 16/568,611”, Stable Heterodimeric Antibody Design With Mutations in the Fc Domain, filed Sep. 12, 2019. [cited by applicant]
“U.S. Appl. No. 17/107,217”, filed Nov. 30, 2020, 219 pages. [cited by applicant]
U.S. Appl. No. 17/343,198, Non-Final Office Action, Mailed On Sep. 27, 2023, 26 pages. [cited by applicant]
U.S. Appl. No. 17/648,747, Advisory Action, Mailed On Jan. 8, 2025, 6 pages. [cited by applicant]
U.S. Appl. No. 17/648,747, Final Office Action, Mailed On Oct. 25, 2024, 10 pages. [cited by applicant]
U.S. Appl. No. 17/648,747, Non-Final Office Action, Mailed On Jun. 3, 2024, 10 pages. [cited by applicant]
U.S. Appl. No. 17/648,747, Notice of Allowance, Mailed On Feb. 18, 2025, 10 pages. [cited by applicant]
U.S. Appl. No. 17/652,557, Final Office Action, Mailed On Oct. 25, 2024, 9 pages. [cited by applicant]
U.S. Appl. No. 17/652,557, Non-Final Office Action, Mailed On Jun. 3, 2024, 10 pages. [cited by applicant]
U.S. Appl. No. 17/652,557, Notice of Allowance, Mailed On Jan. 17, 2025, 9 pages. [cited by applicant]
Braden , “Structural Features of the Reactions Between Antibodies and Protein Antigens”, The FASEB Journal, vol. 9, Issue 1, Jan. 1995, pp. 9-16. [cited by applicant]
Briney et al., “Commonality Despite Exceptional Diversity in the Baseline Human Antibody Repertoire”, Nature; vol. 566, No. 7744, Feb. 2019, 28 pages. [cited by applicant]
Deyev et al., “Modern Technologies for Creating Synthetic Antibodies for Clinical Application”, Acta Naturae, vol. 1, No. 1, Apr. 2009, pp. 32-50. [cited by applicant]
Dockal et al., “Five Recombinant Fragments of Human Serum Albumin-tools for the Characterization of the Warfarin Binding Site”, Protein Science, vol. 9, No. 8, Aug. 2000, pp. 1455-1465. [cited by applicant]
Dufner et al., “Harnessing Phage and Ribosome Display for Antibody Optimisation”, Trends in Biotechnology, vol. 24, No. 11, 2006, pp. 523-529. [cited by applicant]
Feng et al., “Dual Function Antibody Drug Substance Research Study Progress”, Chinese Medical Bio Technology, vol. 9, No. 4, Aug. 2014, pp. 1-6. [cited by applicant]
Feng et al., “Research Progress of Bifunctional Antibody Drugs”, Chinese Medical Biotechnology, vol. 9, No. 4, Aug. 31, 2014, pp. 291-293. [cited by applicant]
Hamel et al., “The Role of the VL- and VH-Segments in the Preferential Reassociation of Immunoglobulin Subunits”, Molecular Immunology, vol. 23, No. 5, May 1986, pp. 503-510. [cited by applicant]
Ionescu et al., “Contribution of Variable Domains to the Stability of Humanized IgG1 Monoclonal Antibodies”, Journal of Pharmaceutical Sciences, vol. 97, No. 4, Apr. 2008, pp. 1414-1426. [cited by applicant]
Jaeger , “Clinical Immunology and Allergology”, Medicine, Second Edition, vol. 2, 1990, 9 pages. [cited by applicant]
Kaloff et al., “Coordination of Immunoglobulin Chain Folding and Immunoglobulin Chain Assembly is Essential for the Formation of Functional IgG”, Immunity, vol. 2, Jun. 1995, pp. 629-637. [cited by applicant]
Klein et al., “The Use of CrossMAb Technology for the Generation of bi- and Multispecific Antibodies”, Monoclonal Antibody, vol. 8, No. 6, Jun. 10, 2016, pp. 1010-1020. [cited by applicant]
Kolfschonten et al., “Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange”, Science, vol. 317, No. 5844, Sep. 14, 2007, pp. 1554-1557. [cited by applicant]
Lloyd et al., “Modelling the Human Immune Response: Performance of a 1011 Human Antibody Repertoire Against a Broad Panel of Therapeutically Relevant Antigens”, Protein Engineering, Design and Selection, vol. 22, No. 3,… [cited by applicant]
Maccallum et al., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography”, Journal of Molecular Biology, vol. 262, No. 5, Oct. 11, 1996, pp. 732-745. [cited by applicant]
Martin , “Protein Sequence and Structure Analysis of Antibody Variable Domains”, Antibody Engineering, vol. 2, Jan. 2010, pp. 33-51. [cited by applicant]
McCann et al., “Peptide Tags for Labeling Membrane Proteins in Live Cells with Multiple Fluorophores”, Bio Techniques, vol. 38, No. 6, Jun. 2005, pp. 945-951. [cited by applicant]
Osborn et al., “Pharmacokinetic and Pharmacodynamics Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys”, Journal of Pharmacology and Experimental Therapeutics, vol. 303, No. 2, Nov. 2002… [cited by applicant]
Piche-Nicholas et al., “Changes in Complementarity-determining Regions Significantly Alter IgG Binding to the Neonatal Fc Receptor (FcRn) and Pharmacokinetics”, Monoclonal Antibodies (MAbs), vol. 10, No. 1, Jan. 2018, p… [cited by applicant]
Shields et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR”, Journal of Biological Chemistry, vol. 276, … [cited by applicant]
Spiess et al., “Alternative Molecular Formats and Therapeutic Applications for Bispecific Antibodies”, Molecular Immunology, vol. 67, Oct. 2015, pp. 95-106. [cited by applicant]
Tao et al., “Biochemistry”, World Publishing Xi'an Co., Ltd., Aug. 31, 2010, p. 234. [cited by applicant]
Tu et al., “Generation and Characterization of Chimeric Antibodies against NS3, NS4, NS5, and Core Antigens of Hepatitis C Virus”, Clinical & Vaccine Immnology, vol. 17, No. 6, Jun. 2010, pp. 1040-1047. [cited by applicant]
Verheesen et al., “Selection by Phage Display of Single Domain Antibodies Specific to Antigens in Their Native Conformation”, Methods in Molecular Biology, vol. 911, Jul. 12, 2012, pp. 81-104. [cited by applicant]
Wiens et al., “Mutation of a Single Conserved Residue in VH Complementarity-Determining Region 2 Results in a Severe Ig Secretion Defect”, The Journal of Immunology, vol. 167, No. 4, Aug. 2001, pp. 2179-2186. [cited by applicant]
Wu et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues”, Journal of Molecular Biology, vol. 294, Nov. 1999, pp. 151-162. [cited by applicant]
Yarilin , “Fundamentals of Immunology”, Textbooks for Medical Students, Manual Moscow, 1999, pp. 172-174. [cited by applicant]